QUINCE THERAPEUTICS, INC. – Trademark Portfolio
Entity Type: 03
QUINCE THERAPEUTICS, INC. holds 11 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 8 filings in this category. The portfolio also extends into Class 42 (Computer & Scientific) across 3 Nice Classification classes. Currently, 3 trademarks are registered and 2 are pending. Notable registered marks include ERYKIT, QUINCE, and CORTEXYME. The owner is based in SOUTH SAN FRANCISCO, CA.
269 EAST GRAND AVENUE
SOUTH SAN FRANCISCO, CA 94080
Showing of trademarks Trademarks
Trademark Classifications
QUINCE THERAPEUTICS, INC.'s trademark portfolio spans 3 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Scientific and technological services; industrial analysis and research services
Frequently Asked Questions
How many trademarks does QUINCE THERAPEUTICS, INC. have?
QUINCE THERAPEUTICS, INC. has 11 U.S. trademarks filed with the USPTO. Of these, 3 registered, 2 pending, 5 abandoned, 1 cancelled.
What trademark classes does QUINCE THERAPEUTICS, INC. file in?
QUINCE THERAPEUTICS, INC. files trademarks across 3 Nice Classification classes. The most active classes are Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific), Class 10 (Medical Apparatus). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.
What are QUINCE THERAPEUTICS, INC.'s most well-known trademarks?
QUINCE THERAPEUTICS, INC.'s registered trademark portfolio includes well-known marks such as ERYKIT, QUINCE, and CORTEXYME. These are among 3 currently registered trademarks in the portfolio.
What is QUINCE THERAPEUTICS, INC.'s trademark registration success rate?
QUINCE THERAPEUTICS, INC. has a 33% trademark registration rate, with 3 out of 9 resolved applications resulting in successful registration. Currently, 2 applications are pending review.